The β-endorphin role in stress-related psychiatric disorders

Current Drug Targets

Volumn 10, Issue 11, 2009, Pages 1096-1108

  Merenlender Wagner, Avia ^a   Dikshtein, Yahav ^a   Yadid, Gal ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Anxiety; Depression; Opioids; Post traumatic stress disorder (PTSD)

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ENDORPHIN; CITALOPRAM; CODEINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DOPAMINE; DULOXETINE; FLUOXETINE; KAPPA OPIATE RECEPTOR; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MU OPIATE RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; PAROXETINE; PROOPIOMELANOCORTIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL WITHDRAWAL; AMYGDALOID NUCLEUS; ANHEDONIA; ANXIETY DISORDER; ARCUATE NUCLEUS; BEHAVIOR; CHRONIC DRUG ADMINISTRATION; DEPRESSION; DISEASE MODEL; DOPAMINE RELEASE; DRUG CLASSIFICATION; DRUG MECHANISM; EXTRACELLULAR FLUID; FLINDERS SENSITIVE LINE RAT; GENE EXPRESSION; HUMAN; LEARNING; MAJOR DEPRESSION; MEMORY; MESOLIMBIC DOPAMINERGIC SYSTEM; MONOAMINERGIC SYSTEM; MOTIVATION; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN UPTAKE; NUCLEUS ACCUMBENS; POSTTRAUMATIC STRESS DISORDER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; PSYCHOTHERAPY; RAT STRAIN; RECEPTOR AFFINITY; REINFORCEMENT; REVIEW; REWARD; SEROTONIN RELEASE; STRESS; SYMPTOMATOLOGY; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BETA-ENDORPHIN; DISEASE MODELS, ANIMAL; MEMORY; RATS; RATS, SPRAGUE-DAWLEY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 70450207474     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789735147     Document Type: Review

References (208)

1. Terenius L, Wahlstro A. Inhibitor(s) of narcotic receptor-binding in brain extracts and cerebrospinal-fluid. Acta Pharmacologica et Toxicologica 1974; 35: 55.
2. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258: 577-580
3. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979; 76: 6666-6670
4. Goldstein A, Fischli W, Lowney LI, Hunkapiller M, Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci U S A 1981; 78: 7219-7223
5. Bradbury AF, Smyth DG, Snell CR. Lipotropin: precursor to two biologically active peptides. Biochem Biophys Res Commun 1976; 69: 950-956
6. van Ree JM. Reinforcing stimulus properties of drugs. Neuropharmacology 1979; 18: 963-969
7. Goeders NE, Lane JD, Smith JE. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 1984; 20: 451-455
8. Belluzzi JD, Stein L. Enkephalin may mediate euphoria and drivereduction reward. Nature 1977; 266: 556-558 (Pubitemid 8079248)
9. Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN, et al. Nucleotide sequence of cloned cDNA for bovine corticotropin- beta-lipotropin precursor. Nature 1979; 278: 423-427 (Pubitemid 9130699)
10. Kakidani H, Furutani Y, Takahashi H, Noda M, Morimoto Y, Hirose T, et al. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 1982; 298: 245-249 (Pubitemid 12089406)
11. Comb M, Seeburg PH, Adelman J, Eiden L, Herbert E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 1982; 295: 663-666
12. Overview of the Endogenous Opioid Systems: Anatomical, Biochemical and Functional Issues. In: Akil H, Bronstein D, Mansour A, eds. Endorphins Opiates and Behavioral Processes. Wiley: New York 1988.
13. Funkelstein L, Toneff T, Mosier C, Hwang SR, Beuschlein F, Lichtenauer UD, et al. Major role of cathepsin L for producing the peptide hormones ACTH, beta-endorphin, and alpha-MSH, illustrated by protease gene knockout and expression. J Biol Chem 2008; 283: 35652-35659
14. Berczi I, Chalmers IM, Nagy E, Warrington RJ. The immune effects of neuropeptides. Baillieres Clin Rheumatol 1996; 10: 227-257
15. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-284
16. Dalayeun JF, Nores JM, Bergal S. Physiology of beta-endorphins. A close-up view and a review of the literature. Biomed Pharmacother 1993; 47: 311-320
17. Zakarian S, Smyth DG. beta-Endorphin is processed differently in specific regions of rat pituitary and brain. Nature 1982; 296: 250-252 (Pubitemid 12072140)
18. Bloom FE, Rossier J, Battenberg EL, Bayon A, French E, Henriksen SJ, et al. beta-endorphin: cellular localization, electrophysiological and behavioral effects. Adv Biochem Psychopharmacol 1978; 18: 89-109.
19. Tseng LF, Wang Q. Forebrain sites differentially sensitive to betaendorphin and morphine for analgesia and release of Metenkephalin in the pentobarbital-anesthesized rat. J Pharmacol Exp Ther 1992; 261: 1028-1036
20. Loh HH, Tseng LF, Wei E, Li CH. beta-endorphin is a potent analgesic agent. Proc Natl Acad Sci U S A 1976; 73: 2895-2898
21. Foley KM, Kourides IA, Inturrisi CE, Kaiko RF, Zaroulis CG, Posner JB, et al. beta-Endorphin: analgesic and hormonal effects in humans. Proc Natl Acad Sci U S A 1979; 76: 5377-5381
22. Bloom F, Segal D, Ling N, Guillemin R. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 1976; 194: 630-632
23. Kreek MJ. Effects of opiates, opioid antagonists and cocaine on the endogenous opioid system: clinical and laboratory studies. NIDA Res Monogr 1992; 119: 44-48
24. Roth-Deri I, Green-Sadan T, Yadid G. Beta-endorphin and druginduced reward and reinforcement. Prog Neurobiol 2008; 86: 1-21.
25. Van Ree JM, Niesink RJ, Van Wolfswinkel L, Ramsey NF, Kornet MM, Van Furth WR, et al. Endogenous opioids and reward. Eur J Pharmacol 2000; 405: 89-101.
26. De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci 2002; 22: 3321-3325
27. Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185-193
28. Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS. Betaendorphin- induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 1991; 104: 51-56
29. Doron R, Fridman L, Yadid G. Dopamine-2 receptors in the arcuate nucleus modulate cocaine-seeking behavior. Neuroreport 2006; 17: 1633-1636 (Pubitemid 44454771)
30. Simmons D, Self DW. Role of Mu- and Delta-Opioid receptors in the nucleus accumbens in cocaine-seeking behavior. Neuropsychopharmacology 2009; 34: 1946-1957
31. Churchill L, Roques BP, Kalivas PW. Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors. Psychopharmacology (Berl) 1995; 120: 347-355
32. Stinus L, Cador M, Le Moal M. Interaction between endogenous opioids and dopamine within the nucleus accumbens. Ann N Y Acad Sci 1992; 654: 254-273
33. Roth-Deri I, Zangen A, Aleli M, Goelman RG, Pelled G, Nakash R, et al. Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens. J Neurochem 2003; 84: 930-938 (Pubitemid 36330647)
34. Yadid G, Friedman A. Dynamics of the dopaminergic system as a key component to the understanding of depression. Prog Brain Res 2008; 172: 265-286
35. Zangen A, Nakash R, Yadid G. Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study. J Neurochem 1999; 73: 2569-2574
36. Anwer J, Soliman MR. Ethanol-induced alterations in betaendorphin levels in specific rat brain regions: modulation by adenosine agonist and antagonist. Pharmacology 1995; 51: 364-369
37. Tekes K, Gyenge M, Hantos M, Csaba G. Effect of beta-endorphin imprinting during late pregnancy on the brain serotonin and plasma nocistatin levels of adult male rats. Horm Metab Res 2007; 39: 479-481 (Pubitemid 47204189)
38. Martin WR. Opioid antagonists. Pharmacol Rev 1967; 19: 463-521.
39. Zhang Y, Pan YX, Kolesnikov Y, Pasternak GW. Immunohistochemical labeling of the mu opioid receptor carboxy terminal splice variant mMOR-1B4 in the mouse central nervous system. Brain Res 2006; 1099: 33-43. (Pubitemid 44080086)
40. Tao R, Auerbach SB. mu-Opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res 2005; 1049: 70-79 (Pubitemid 40814576)
41. Gaveriaux-Ruff C, Kieffer BL. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002; 36: 62-71. (Pubitemid 35041867)
42. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66: 285-306. (Pubitemid 34518287)
43. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998; 17: 886-897 (Pubitemid 28077643)
44. Slugg RM, Hayward MD, Ronnekleiv OK, Low MJ, Kelly MJ. Effect of the mu-opioid agonist DAMGO on medial basal hypothalamic neurons in beta-endorphin knockout mice. Neuroendocrinology 2000; 72: 208-217
45. Hayward MD, Pintar JE, Low MJ. Selective reward deficit in mice lacking beta-endorphin and enkephalin. J Neurosci 2002; 22: 8251-8258
46. Biegler P. Autonomy, stress, and treatment of depression. BMJ 2008; 336: 1046-1048
47. Danese A. Genetic opportunities for psychiatric epidemiology: on life stress and depression. Epidemiol Psichiatr Soc 2008; 17: 201-210
48. El Hage W, Powell JF, Surguladze SA. Vulnerability to depression: what is the role of stress genes in gene x environment interaction? Psychol Med 2009; 39: 1407-1411
49. Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008; 11: 198-209. (Pubitemid 351874183)
50. Medvedev A, Igosheva N, Crumeyrolle-Arias M, Glover V. Isatin: role in stress and anxiety. Stress 2005; 8: 175-183
51. Shekhar A, Truitt W, Rainnie D, Sajdyk T. Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 2005; 8: 209-219 (Pubitemid 43163254)
52. Pintor L, Torres X, Navarro V, Martinez de Osaba MA, Matrai S, Gasto C. Corticotropin-releasing factor test in melancholic patients in depressed state versus recovery: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1027-1033 (Pubitemid 46810093)
53. Nikolarakis KE, Almeida OF, Herz A. Stimulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor (in vitro). Brain Res 1986; 399: 152-155
54. Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry 2001; 26: 5-9. (Pubitemid 34003368)
55. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, Florio LP. Effective disorders in five United States communities. A Psychol Med 1988; 18: 141-153 (Pubitemid 18071642)
56. Angst J. Epidemiology of depression. Psychopharmacology (Berl) 1992; 106 Suppl: S71-4.
57. Whybrow PG, Akiskal HS, McKinney WT. Mood Disorders: Toward a New Psychobiology. Plenum Press: New York 1984.
58. von Knorring L, Perris C, Eisemann M, Eriksson U, Perris H. Pain as a symptom in depressive disorders. part II: relationship to personality traits as assessed by means of KSP. Pain 1983; 17: 377-384 (Pubitemid 14211853)
59. von Knorring L, Perris C, Oreland L, Eisemann M, Eriksson UPH. Pain as a symptom in depressive disorders and its relationship to platelet monoamine oxidase activity. J Neural Transm 1984; 60: 1-9. (Pubitemid 14065249)
60. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY, Lowy MT, eds. Psychopharmacology: The Third Generation of Progress. Raven: New York 1987; pp. 513-526
61. Maes M, Meltzer HY. The Serotonin Hypothesis of Major Depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology The Fourth Generation of Progress. Raven; New York 1995; pp. 933- 944
62. Stokes PE, Pick GR, Stoll PM, Nunn WD. Pituitary-adrenal function in depressed patients: resistance to dexamethasone suppression. J Psychiatr Res 1975; 12: 271-281
63. Janowsky DS, Risch SC, Ziegler M, Kennedy B, Huey L. A cholinomimetic model of motion sickness and space adaptation syndrome. A t Space Environ Med 1984; 55: 692-696
64. Janowsky DS, Risch C, Parker D, Huey L, Judd L. Increased vulnerability to cholinergic stimulation in affective-disorder patients [proceedings]. Psychopharmacol Bull 1980; 16: 29-31. (Pubitemid 11226840)
65. Janowsky DS, Overstreet DH. The cholinergic hypothesis of depression. Psychopharmacology: The Fourth Generation of Progress. Raven: New York 1995; pp. 944-957
66. Risch SC. beta-Endorphin hypersecretion in depression: possible cholinergic mechanisms. Biol Psychiatry 1982; 17: 1071-1079
67. Gershon ES, Berrettini W, Nurnberger JI, Goldin LR. Genetics of afective illness. In: Meltzer HYE, Ed. Psychopharmacology: The Third Generation of Progress. New York: Raven; 1987: 481-492
68. Bauer M, Adli M, Baethge C, Berghofer A, Sasse J, Heinz A, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003; 48: 440-448 (Pubitemid 37295201)
69. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12: 2985-2992 (Pubitemid 44184631)
70. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004; 65: 5-10.
71. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: sys tematic review and meta-analysis. Arch Gen Psychiatry 2006; 63: 1217-1223 (Pubitemid 44708080)
72. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed- Moussa S, Grupper D, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-688 (Pubitemid 46878668)
73. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001; 15: 941-954
74. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008; 69: 1404-1415
75. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet 2009; 373: 746-758
76. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22: 323-329 (Pubitemid 47530836)
77. Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2005; 1: 289-299
78. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 1522-1526 (Pubitemid 44787433)
79. Davidson JR, Stein DJ, Shalev AY, Yehuda R. Posttraumatic stress disorder: acquisition, recognition, course, and treatment. J Neuropsychiatry Clin Neurosci 2004; 16: 135-147 (Pubitemid 38560896)
80. DSM. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). American Psychiatric Press: Washington, D.C. 1994.
81. Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991: 216-222
82. Jang KL, Stein MB, Taylor S, Asmundson GJ, Livesley WJ. Exposure to traumatic events and experiences: aetiological relationships with personality function. Psychiatry Res 2003; 120: 61-69 (Pubitemid 37123144)
83. Schoenfeld FB, Marmar CR, Neylan TC. Current concepts in pharmacotherapy for posttraumatic stress disorder. Psychiatr Serv 2004; 55: 519-531
84. Nutt D DJ, ed. Post-Traumatic Stress Disorder Diagnosis, Management and Treatment. Taylor & Francis: London 2000.
85. Davidson JR, Stein DJ, Shalev AY, Yehuda RJ. Posttraumatic stress disorder: acquisition, recognition, course, and treatment. Neuropsychiatry Clin Neurosci 2004; 16: 135-147 (Pubitemid 38560896)
86. Van Der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001; 16: S49-64.
87. Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008; 9: 787-794
88. Liebert R, Gavey N. "There are always two sides to these things" Managing the dilemma of serious adverse effects from SSRIs. Soc Sci Med 2009; 68: 1882-1891.
89. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci 1993; 30: 255-263 (Pubitemid 24039004)
90. Rauch SL. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 1996; 53: 380-387
91. Rauch SL. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry 2000; 47: 769-776
92. Koenigs M, Huey ED, Raymont V, Cheon B, Solomon J, Wassermann EM, et al. Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nat Neurosci 2008; 11: 232-237 (Pubitemid 351170492)
93. Bloom FE, Kupfer DJ. Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York 1995.
94. Clement Y, Calatayud F, Belzung C. Genetic basis of anxiety-like behaviour: a critical review. Brain Res Bull 2002; 57: 57-71. (Pubitemid 34097771)
95. Horowitz ZP. Elective block or rat mouse killing by antidepressants. Life Sci 1965; 4: 1909-1912
96. Ueki S. Mouse-killing behaviour (muricide) in the rat and the effect of antidepressants. In: Langer SZ, Takahashi R, Segawa T, Briley M, ed. New Vistas in Depression. Pergamon Press; New York 1982; pp. 187-194
97. Malick JB. Yohimbine potentiation as a predictor of antidepressant action. In: Enna SJ, Malick JB, Richelson E, eds. Antidepressants: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven; 1981: 141-155
98. Quinton RM. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol Chemother 1963; 21: 51-66.
99. Babington RG. Antidepressives and the kindling effect. In: Fielding S, Lal H, eds. Antidepressants. Futura, Mount Kisco: New York 1975; pp. 113-124
100. Babington RG, Wedeking PW. The pharmacology of seizures induced by sensitization with low intensity brain stimulation. Pharmacol Biochem Behav 1973; 1: 461-467
101. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25: 295-330.
102. Everett GM. The DOPA response potentiation test and its use in screening for antidepressant drugs. In: Garattini S, Dukes MNG, eds. Antidepressant drug Amsterdam. Excerpta Medica: Amsterdam 1967; pp. 164-167
103. Sigg EB, Hill RT. The effect of imipramine on central adrenergic mechanisms. . In: Brill H, ed. Neuro-psycho-phar-macology. Excerpta Medica: Amsterdam 1967; pp. 367-372
104. Nagayama H, Hingtgen JN, Aprison MH. Pre- and postsynaptic serotonergic manipulations in an animal model of depression. Pharmacol Biochem Behav 1980; 13: 575-579 (Pubitemid 10024777)
105. Nagayama H, Hingtgen JN, Aprison MH. Postsynaptic action by four antidepressive drugs in an animal model of depression. Pharmacol Biochem Behav 1981; 15: 125-130 (Pubitemid 11083232)
106. Cairncross KD, Wren A, Cox B, Schnieden H. Effects of olfactory bulbectomy and domicile on stress-induced corticosterone release in the rat. Physiol Behav 1977; 19: 485-487 (Pubitemid 8317179)
107. Cairncross KD, Cox B. A new model for the detection of antidepressant drugs: Olfactory bulbectomy in the rat compared with existing models. J Pharmacol Methods 1978: 131-143 (Pubitemid 9175590)
108. Cairncross KD, Cox B, Forster C, Wren AF. Olfactory projection systems, drugs and behaviour: a review. Psychoneuroendocrinology 1979; 4: 253-272 (Pubitemid 10209956)
109. Einon D, Morgan MJ, Sahakian BJ. The development of intersession habituation and emergence in socially reared and isolated rats. Dev Psychobiol 1975; 8: 553-559
110. Sahakian BJ, Robbins TW. Isolation-rearing enhances tail pinchinduced oral behavior in rats. Physiol Behav 1977; 18: 53-58
111. Sahakian BJ, Robbins TW, Morgan MJ, Iversen SD. The effects of psychomotor stimulants on stereotypy and locomotor activity in socially- deprived and control rats. Brain Res 1975; 84: 195-205.
112. Hatotani N, Nomura J. Changes of brain monoamines in the animal model for depression. In: Langer SZ, Takahashi R, Segawa T, Briley M, eds. New Vistas in Depression. Pergamon Press: New York 1982; pp. 65-72.
113. Baltzer V, Weiskrantz, L. Antidepressant agents and reversal of diurnal activity cycles in the rat. Biol Psychiatry 1973; 10: 199-209.
114. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-391
115. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336 (Pubitemid 8225714)
116. Porsolt RD, Bertin A, Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978; 51: 291-294
117. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-732 (Pubitemid 8073804)
118. Katz RJ. Animal models and human depressive disorders. Neurosci Biobehav Rev 1981; 5: 231-246
119. Katz RJ, Roth KA, Carroll BJ. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci Biobehav Rev 1981; 5: 247-251
120. Katz RJ, Sibel M. Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds. Pharmacol Biochem Behav 1982; 16: 973-977 (Pubitemid 12081657)
121. Katz RJ, Sibel M. Further analysis of the specificity of a novel animal model of depression - effects of an antihistaminic, antipsychotic and anxiolytic compound. Pharmacol Biochem Behav 1982; 16: 979-982 (Pubitemid 12081658)
122. Kaufman IC, Rosenblum LA. The reaction to separation in infant monkeys: anaclitic depression and conservation-withdrawal. Psychosom Med 1967; 29: 648-675
123. McKinney WT Jr, Bunney WE Jr. Animal model of depression. I. Review of evidence: implications for research. Arch Gen Psychiatry 1969; 21: 240-248
124. Hinde RA, Leighton-Shapiro ME, McGinnis L. Effects of various types of separation experience on rhesus monkeys 5 months later. J Child Psychol Psychiatry 1978; 19: 199-211. (Pubitemid 8400237)
125. Klinger E, Barta SG, Kemble ED. Cyclic activity changes during extinction in rats: a potential model of depression. Anim Learn Behav 1974; 2: 313-316
126. Barrett RJ, White DK. Reward system depression following chronic amphetamine: antagonism by haloperidol. Pharmacol Biochem Behav 1980; 13: 555-559
127. Kokkinidis L, Zacharko RM. Response sensitization and depression following long-term amphetamine treatment in a selfstimulation paradigm. Psychopharmacology (Berl) 1980; 68: 73-76 (Pubitemid 10107878)
128. Leith NJ, Barrett RJ. Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia 1976; 46: 19-25.
129. Leith NJ, Barrett RJ. Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression? Psychopharmacology (Berl) 1980; 72: 9-15.
130. Simpson DM, Annau Z. Behavioral withdrawal following several psychoactive drugs. Pharmacol Biochem Behav 1977; 7: 59-64. (Pubitemid 8186071)
131. Maier SF, Seligman ME. Learned helplessness. Theory and evidence. J Exp Psychol 1976; 105: 3-46.
132. Maier SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 435-446 (Pubitemid 14051222)
133. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997; 134: 319-329 (Pubitemid 28023396)
134. Weiss JM, Cierpial MA, West CH. Selective breeding of rats for high and low motor activity in a swim test: toward a new animal model of depression. Pharmacol Biochem Behav 1998; 61: 49-66.
135. Overstreet DH. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 1993; 17: 51-68.
136. Overstreet DH, Friedman E, Mathe AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005; 29: 739-759 (Pubitemid 40762598)
137. Janowsky DS, Overstreet DH, Nurnberger JI Jr. Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet 1994; 54: 335-344
138. Nutt D, Davidson JRT, Zohar J, eds. Post-traumatic Stress Disorder Diagnosis, Management and Treatment. Taylor & Francis, A Martin Dunitz Book: London 2000.
139. Garrick T, Morrow N, Shalev AY, Eth S. Stress-induced enhancement of auditory startle: an animal model of posttraumatic stress disorder. Psychiatry 2001; 64: 346-354 (Pubitemid 34074163)
140. Koba T, Kodama Y, Shimizu K, Nomura S, Sugawara M, Kobayashi Y, et al. Persistent behavioural changes in rats following inescapable shock stress: a potential model of posttraumatic stress disorder. World J Biol Psychiatry 2001; 2: 34-37
141. Pynoos RS, Ritzmann RF, Steinberg AM, Goenjian A, Prisecaru I. A behavioral animal model of posttraumatic stress disorder featuring repeated exposure to situational reminders. Biol Psychiatry 1996; 39: 129-134 (Pubitemid 26045300)
142. Servatius RJ, Ottenweller JE, Natelson BH. Delayed startle sensitization distinguishes rats exposed to one or three stress sessions: further evidence toward an animal model of PTSD. Biol Psychiatry 1995; 38: 539-546
143. Richter-Levin G. Acute and long-term behavioral correlates of underwater trauma-potential relevance to stress and post-stress syndromes. Psychiatry Res 1998; 79: 73-83. (Pubitemid 28318245)
144. Liberzon I, Krstov M, Young EA. Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrinology 1997; 22: 443-453 (Pubitemid 27431506)
145. Torres IL, Gamaro GD, Vasconcellos AP, Silveira R, Dalmaz C. Effects of chronic restraint stress on feeding behavior and on monoamine levels in different brain structures in rats. Neurochem Res 2002; 27: 519-525 (Pubitemid 34894257)
146. Adamec RE, Burton P, Shallow T, Budgell J. NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure - implications for anxiety associated with posttraumatic stress disorder. Physiol Behav 1999; 65: 723-737 (Pubitemid 29094709)
147. Adamec RE, Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 1993; 54: 101-109 (Pubitemid 23172429)
148. Cohen H, Zohar J, Matar M. The relevance of differential response to trauma in an animal model of posttraumatic stress disorder. Biol Psychiatry 2003; 53: 463-473 (Pubitemid 36331885)
149. Cohen H, Benjamin J, Kaplan Z, Kotler M. Administration of highdose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. Eur Neuropsychopharmacol 2000; 10: 429-435
150. Cohen H, Kaplan Z, Kotler M. CCK-antagonists in a rat exposed to acute stress: implication for anxiety associated with post-traumatic stress disorder. Depress Anxiety 1999; 10: 8-17. (Pubitemid 29404544)
151. Dielenberg RA, Hunt GE, McGregor IS. "When a rat smells a cat": the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience 2001; 104: 1085-1097
152. Morrow BA, Redmond AJ, Roth RH, Elsworth JD. The predator odor, TMT, displays a unique, stress-like pattern of dopaminergic and endocrinological activation in the rat. Brain Res 2000; 864: 146-151
153. Funada M, Hara C. Differential effects of psychological stress on activation of the 5-hydroxytryptamine- and dopamine-containing neurons in the brain of freely moving rats. Brain Res 2001; 901: 247-251 (Pubitemid 32718828)
154. Makino S, Shibasaki T, Yamauchi N, Nishioka T, Mimoto T, Wakabayashi I, et al. Psychological stress increased corticotropinreleasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat. Brain Res 1999; 850: 136-143
155. Ottenweller JE, Natelson BH, Pitman DL, Drastal SD. Adrenocortical and behavioral responses to repeated stressors: toward an animal model of chronic stress and stress-related mental illness. Biol Psychiatry 1989; 26: 829-841
156. Feldman RS, Mayer JS, Quenzer LF. Principles of Neuropsychopharmacology. sinauer Associates, Inc.: Sunderland, Massachusetts 1997.
157. Kesner Y, Zohar J, Merenlender A, Gispan I, Shalit F, Yadid G. WFS1 gene as a putative biomarker for development of posttraumatic syndrome in an animal model. Mol Psychiatry 2009; 14: 86-94.
158. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308-314
159. Martin-Schild S, Gerall AA, Kastin AJ, Zadina JE. Differential distribution of endomorphin 1- and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 1999; 405: 450-471 (Pubitemid 29124064)
160. Lewis ME, Khachaturian H, Watson SJ. Combined autoradiographic- immunocytochemical analysis of opioid receptors and opioid peptide neuronal systems in brain. Peptides 1985; 6 : 37-47. (Pubitemid 16205913)
161. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-29
162. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.
163. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
164. Nikulina EM, Miczek KA, Hammer RP Jr. Prolonged effects of repeated social defeat stress on mRNA expression and function of mu-opioid receptors in the ventral tegmental area of rats. Neuropsychopharmacology 2005; 30: 1096-1103
165. Hopwood SE, Stamford JA. Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphe nuclei. Neuropharmacology 2001; 40: 508-519
166. Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA. Antidepressant- like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci 2002; 72: 143-152 (Pubitemid 35363284)
167. Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA. Antidepressant- like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol 2004; 18: 404-411 (Pubitemid 39382569)
168. Rojas-Corrales MO, Berrocoso E, Mico JA. Role of 5-HT1A and 5-HT1B receptors in the antinociceptive effect of tramadol. Eur J Pharmacol 2005; 511: 21-26
169. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Tramadol induces antidepressant-type effects in mice. Life Sci 1998; 63: PL175-80. (Pubitemid 29369111)
170. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008; 44: 827-836
171. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis 2008; 27: 49-65.
172. Becker WC, Fiellin DA, Gallagher RM, Barth KS, Ross JT, Oslin DW. The association between chronic pain and prescription drug abuse in Veterans. Pain Med 2009; 10: 531-536
173. Liberzon I, Taylor SF, Phan KL, Britton JC, Fig LM, Bueller JA, et al. Altered central micro-opioid receptor binding after psychological trauma. Biol Psychiatry 2007; 61: 1030-1038 (Pubitemid 46551967)
174. Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009; 65: 438-440
175. Darko DF, Risch SC, Gillin JC, Golshan S. Association of betaendorphin with specific clinical symptoms of depression. Am J Psychiatry 1992; 149: 1162-1167
176. France RD, Urban BJ. Cerebrospinal fluid concentrations of betaendorphin in chronic low back pain patients. Influence of depression and treatment. Psychosomatics 1991; 32: 72-77
177. Goodwin GM, Austin MP, Curran SM, Ross M, Murray C, Prentice N, et al. The elevation of plasma beta-endorphin levels in major depression. J Affect Disord 1993; 29: 281-289 (Pubitemid 2021867)
178. Naber D, Pickar D, Post RM, Van Kammen DP, Waters RN, Ballenger JC, et al. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry 1981; 138: 1457-1462 (Pubitemid 11030316)
179. Young EA, Watson SJ, Kotun J, Haskett RF, Grunhaus L, Murphy- Weinberg V, et al. Beta-lipotropin-beta-endorphin response to lowdose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. Arch Gen Psychiatry 1990; 47: 449-457
180. Ward NG, Bloom VL, Friedel RO. The effectiveness of tricyclic antidepressants in the treatment of coexisting pain and depression. Pain 1979; 7: 331-341
181. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-226 (Pubitemid 24210726)
182. Yadid G, Overstreet DH, Zangen A. Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression. Brain Res 2001; 896: 43-47 (Pubitemid 32244145)
183. Yadid G, Zangen A, Herzberg U, Nakash R, Sagen J. Alterations in endogenous brain beta-endorphin release by adrenal medullary transplants in the spinal cord. Neuropsychopharmacology 2000; 23: 709-716 (Pubitemid 30785855)
184. Nestler EJ, Terwilliger RZ, Duman RS. Regulation of endogenous ADP-ribosylation by acute and chronic lithium in rat brain. J Neurochem 1995; 64: 2319-2324
185. Fagergren P, Overstreet DH, Goiny M, Hurd YL. Blunted response to cocaine in the Flinders hypercholinergic animal model of depression. Neuroscience 2005; 132: 1159-1171 (Pubitemid 40602549)
186. Schedlowski M, Fluge T, Richter S, Tewes U, Schmidt RE, Wagner TO. Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 1995; 20: 103-110 (Pubitemid 24325674)
187. Bilkei-Gorzo A, Racz I, Michel K, Mauer D, Zimmer A, Klingmuller D. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008; 33: 425-436
188. Kiefer F, Horntrich M, Jahn H, Wiedemann K. Is withdrawalinduced anxiety in alcoholism based on beta-endorphin deficiency? Psychopharmacology (Berl) 2002; 162: 433-437
189. Grisel JE, Bartels JL, Allen SA, Turgeon VL. Influence of beta- Endorphin on anxious behavior in mice: interaction with EtOH. Psychopharmacology (Berl) 2008; 200: 105-115
190. Marinelli PW, Quirion R, Gianoulakis C. An in vivo profile of betaendorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience 2004; 127: 777-784
191. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003; 23: 5674-5683 (Pubitemid 36807845)
192. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
193. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004; 90: 1258-1268 (Pubitemid 39167359)
194. Hoffman L, Burges Watson P, Wilson G, Montgomery J. Low plasma beta-endorphin in post-traumatic stress disorder. Aust N Z J Psychiatry 1989; 23: 269-273 (Pubitemid 19176208)
195. Hamner MB, Hitri A. Plasma beta-endorphin levels in posttraumatic stress disorder: a preliminary report on response to exercise- induced stress. J Neuropsychiatry Clin Neurosci 1992; 4: 59-63.
196. Kellner M, Baker DG, Yehuda R. Salivary cortisol and PTSD symptoms in Persian Gulf War combatants. Ann N Y Acad Sci 1997; 821: 442-443 (Pubitemid 27343042)
197. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. Am J Psychiatry 1993; 150: 1430.
198. Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol 2002; 17: 181-185 (Pubitemid 34678879)
199. Saxe G, Stoddard F, Courtney D, Cunningham K, Chawla N, Sheridan R, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry 2001; 40: 915-921 (Pubitemid 32667074)
200. Introini-Collison IB, Ford L, McGaugh JL. Memory impairment induced by intraamygdala beta-endorphin is mediated by noradrenergic influences. Neurobiol Learn Mem 1995; 63: 200-205
201. McGaugh JL, Introini-Collison IB, Cahill LF, Castellano C, Dalmaz C, Parent MB, et al. Neuromodulatory systems and memory storage: role of the amygdala. Behav Brain Res 1993; 58: 81-90. (Pubitemid 24024047)
202. Barros DM, Izquierdo LA, Medina JH, Izquierdo I. Pharmacological findings contribute to the understanding of the main physiological mechanisms of memory retrieval. Curr Drug Targets CNS Neurol Disord 2003; 2: 81-94.
203. Tryon WW, McKay D. Memory modification as an outcome variable in anxiety disorder treatment. J Anxiety Disord 2009; 23: 546-556
204. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. Opiates as antidepressants. Curr Pharm Des 2009; 15: 1612-1622
205. Quevedo J, Moretto A, Colvero M, Roesler R, Ferreira MB. The Nmethyl- D-aspartate receptor blocker MK-801 prevents the facilitatory effects of naloxone and epinephrine on retention of inhibitory avoidance task in rats. Behav Pharmacol 1997; 8: 471-474 (Pubitemid 127503076)
206. Katzen-Perez KR, Jacobs DW, Lincoln A, Ellis RJ. Opioid blockade improves human recognition memory following physiological arousal. Pharmacol Biochem Behav 2001; 70: 77-84. (Pubitemid 32786969)
207. Paxinos and Watson G. The Rat Brain in Stereotaxic Coordinates. 4th ed. Diego S, wed. Academic Press; San Diego 1998.
208. Zangen A, Nakash R, Roth-Deri I, Overstreet DH, Yadid G. Impaired release of beta-endorphin in response to serotonin in a rat model of depression. Neuroscience 2002; 110: 389-393 (Pubitemid 34242769)